Anti-interleukin-6 receptor antibody therapy -From Bedside to Bench-

Japanese Journal of Clinical Immunology

Volumn 29, Issue 5, 2006, Pages 289-294

  Nishimoto, Norihiro ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Castleman's disease; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ATLIZUMAB; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BIOSYNTHESIS; HOSPITAL INFORMATION SYSTEM; HUMAN; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; GIANT LYMPH NODE HYPERPLASIA; HUMANS; POINT-OF-CARE SYSTEMS; RECEPTORS, INTERLEUKIN-6; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34248341441     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.29.289     Document Type: Article

References (14)

1. Hirano T, et al.: Complementary DNA for a novel human interleukin (BSF-2) that induces B cell lymphocytes to produce immunoglobulin. Nature 324: 73–76, 1986.
2. Wolvekamp MC, et al.: Interleukin-6: Historical background, genetics and biological significance. Immunol Lett 24: 1–9, 1990.
3. Castleman B, et al.: Localized mediastinal lymph node hyperplasia resembling thymoma. Cancer 9: 822–830, 1956.
4. Keller AR, et al.: Hyalin-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29: 670–683, 1972.
5. Yoshizaki K, et al.: Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman's disease. Blood 74: 1360–1367, 1989.
6. Nishimoto N, et al.: Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95: 56–61, 2000.
7. Nishimoto N, et al.: Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman's disease. Blood 106: 2627–2632, 2005.
8. Folkman J: Angiogenesis in cancer, vascular, rheumatoid, and other disease. Nat Med 1: 27–31, 1995.
9. Colville-Nash PR, et al.: Angiogenesis and rheumatoid arthritis: Pathogenic and therapeutic implications. Ann Rheum Dis 51: 919–925, 1992.
10. Nagashima M, et al.: Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol 22: 1624–30, 1995.
11. Bottomley MJ, et al.: Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): Specific upregulation by tumor necrosis factor-alpha (TNF-α) in synovial fluid. Clin Exp Immunol 117: 171–176, 1999.
12. Fava RA, et al.: Vascular permeability factor/ endothelial growth factor (VPF/VEGF): Accumulation and expression in human synovial luids and rheumatoid synovial tissue. J Exp Med 180: 341–346, 1994.
13. Ballara S, et al.: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 44: 2055–2064, 2001.
14. Nakahara H, et al.: Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum 48: 1521–1529, 2003.